Atrial fibrillation is a common heart condition characterized by a rapid, irregular heartbeat stemming from the heart's upper chamber. It is a leading cause of stroke from clots that form in a small ...
Anticoagulation is a critical component in the treatment of cardiovascular diseases. Large randomised controlled trials have ...
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, ...
Edwards, AtriCure, Boston Scientific, and Medtronic report strong earnings driven by TAVR, PFA, and cardiac ablation growth in 2025.
Mason, Ohio-based AtriCure, a specialist in surgical treatments and therapies for atrial fibrillation, left atrial appendage management, and post-operative pain management, saw substantial revenue ...
A first look at the implant success and sealing efficacy of a dual-seal left atrial appendage occlusion (LAAO) device that’s in development reveals successful implantation in 99.8% of people with ...
A MULTICENTRE study has shown that left atrial appendage closure (LAAC) is associated with acute increases in left atrial pressure (LAP) during and immediately after the procedure, although no adverse ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results